Express Pharma
Home  »  COVID-19 Updates  »  COVAXIN demonstrates protective efficacy in animal studies: Bharat Biotech

COVAXIN demonstrates protective efficacy in animal studies: Bharat Biotech

A two-dose vaccination regimen, administered in 20 rhesus macques, showed increasing SARS-CoV-2 specific IgG and neutralizing antibodies, reducing replication of the virus in the nasal cavity, throat, and lung tissues

1 2,064
Read Article

Bharat Biotech, COVAXIN, its COVID-19 vaccine candidate has shown positive efficacy in animal studies.

“Bharat Biotech proudly announces the animal study results of COVAXIN – These results demonstrate the protective efficacy in a live viral challenge model,” tweeted the company.

The indigenously developed vaccine by the Indian Council of Medical Research (ICMR) and Bharat Biotech, is undergoing at 12 institutes across India.

The company informed through a statement, “A two-dose vaccination regimen of inactivated SARS-CoV-2 vaccine candidates was administered in 20 rhesus macaques (divided into four groups equally). One group was administered with placebo, while three groups were immunised with three different vaccine candidates at 0 and 14 days. All the macaques were exposed to viral challenge 14 days after the second dose.”

It also divulged, “The results showed protective efficacy, increasing SARS-CoV-2 specific IgG and neutralizing antibodies, reducing replication of the virus in the nasal cavity, throat, and lung tissues of monkey. No evidence of pneumonia was observed by histopathological examination in vaccinated groups, unlike the placebo group. Adverse events were not seen in animals immunized with a two-dose vaccination regimen.”

It concluded, “The vaccine candidate was found to generate robust immune responses. Thus, preventing infection and disease in the primates upon high amounts of exposure to live SARS-CoV-2 virus.

1 Comment
  1. VARA KUMAR says

    Many of the vaccines are stored in Cold temperatures and currently all vaccine manufacturers after primary packaging the unlabelled product are being kept on hold for about 2 to 12 hours to dry the surface and then wiping with dry cloth which is a tedious work to the pharmaceutical packaging operations.

    The challenge of cold/wet labeling is driven by two issues:

    > Cold temperatures
    > Water on the substrate surface

    Cold temperatures cause pressure-sensitive adhesives to become firm and drop in initial tack. This means adhesives that perform well at high temperatures now lose too much tack to work well on the cold/wet surface.

    The amount of condensation on the surface is also a major concern. A pressure-sensitive label material will not stick to water (condensation) – due to the deadening of the tack.

    This is a situation where TR-2015 & TR-2016 is designed to work.
    A surface with limited surface moisture at reduced temperatures,

    Avery Dennison TR-2015 and TR-2016 label is an exciting innovation for cold/wet labeling, it is however not without its limitations. Understanding the limitations of the adhesive before labeling can minimize the effort required to have labeling success. The key to success is to reduce the amount of water on the surface of the container.

    Avery Dennison TR-2015 and TR-2016 adhesive is a working solution for these problem applications.

    Please contact your Avery Dennison representative with any questions you may have regarding the adhesive and applying it to your labeling operation..

    This disclaimer informs readers that the views, thoughts, and opinions expressed in the text belong solely to the author, and not necessarily to the author’s employer, organization, committee or other group or individual.

Leave A Reply

Your email address will not be published.